Matching-Adjusted Indirect Comparison of Risankizumab Versus Deucravacitinib in Patients with Moderate-to-Severe Plaque Psoriasis
This indirect comparison demonstrates that risankizumab has higher rates of skin clearance and greater improvements in QoL than deucravacitinib. This study will help inform healthcare providers in their treatment and management strategy of PsO.
Authors
- Manish Patel (ORCID: https://orcid.org/0009-0002-6139-6873)
- April Wang Armstrong (ORCID: https://orcid.org/0000-0003-0064-8707)
- Shanyu Fang (ORCID: https://orcid.org/0009-0004-5664-9789)
- Paolo Gisondi (ORCID: https://orcid.org/0000-0002-1777-9001)
- Bruce E Strober (ORCID: https://orcid.org/0000-0002-8394-2057)
- Ahmed M. Soliman (ORCID: https://orcid.org/0009-0008-8632-1396)
Institutions
- University of Southern California (US)
- University of Verona (IT)
- AbbVie (United States) (US)
- Yale University (US)
- Central Dermatology (US)
Publication Details
- Journal
- Dermatology and Therapy
- Published
- 2024-10-25
- DOI
- https://doi.org/10.1007/s13555-024-01293-y
- Citations
- 1
- Primary Topic
- Psoriasis: Treatment and Pathogenesis
- Type
- article
- Field-Weighted Citation Impact
- 0.24
Funders
- AbbVie